ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BTTC / forecast
CELZ (20) CRIS (27) LIMN (35) PMCB (34) ⌘ Pro Terminal →

Black Titan Corporation (BTTC) 12-Month Stock Forecast & Price Target Cone

$0.31 -3.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.31

Black Titan Corporation (BTTC) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $4.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BTTC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BTTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Black Titan Corporation (NASDAQ: BTTC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.31 (-3.17% 1D, market cap $4.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BTTC ranks #522 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BTTC compare to CELZ and CRIS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BTTC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CELZ (Creative Medical Technology Holdings Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $5.0M) and CRIS (Curis Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M). Among the 5-stock peer group, BTTC leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BTTC?
▼

Per BTTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-07-31, CIK 0002034400), Black Titan Corporation generated $869.2K in revenue, -$163.2K in net income, and -$143.2K in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.31 (-0.76%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510038
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Cash (10)Whales (6)SEC (10)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.7% Base Target
$11 Bull$0 Base$0 Bear
📬 FREE BTTC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BTTC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY BTTC SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+10/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 38.6% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
46
Grade D$0.44-15.9% Next Q
Q2 (-2Q)
43
Grade D$0.37-5.4% Next Q
Q3 (-1Q)
41
Grade D$0.35-11.4% Next Q
Current
38
Grade D-$0.31-7.8% Hist 90D α
Trajectory: D (46) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BTTC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BTTC currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.44) and Max Pain ($0.33) forces dealer call-delta covering toward $10.55.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BTTC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BTTC Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”
YES 38%NO 62%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your BTTC Position Size: $10,000

Shares at $0.31: 32258.1 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $0.22
$7,097
$-2,903 (-29.0%)
12M Consensus BaseTarget $0.28
$9,032
$-968 (-9.7%)
12M Bull Case BreakoutTarget $10.55
$340,323
+$330,323 (+3303.2%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$074%A
Goldman SachsSector Coverage LeadUNDERPERFORM$1069%B
JP MorganUS Large-Cap ResearchSELL$058%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BTTC)

  • ✓Walkthrough of BTTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BTTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -74.80%▼ DESCENDING CHANNEL
2026-11-03O $0.35H $0.35L $0.31C $0.31VOL 208.4K
RES: $0.84SUP: $0.16SMA50: $0.44SMA200: $1.02
$2.84$2.15$1.47$0.78$0.10RES $0.84SUP $0.16$0.312026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BTTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BTTC Butterfly Map → + Track BTTC →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BTTC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BTTC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BTTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BTTC)

Health Care Rank #522 of 1015 ⚔️ CELZ vs BTTC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BTTC vs. CELZ, CRIS, LIMN, PMCB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Black Titan Corporation (BTTC) ranks #522 by composite RQD confidence (38/100, grade D-) and #947 by equity capitalization ($4.8M). Within this direct 5-issuer industry benchmark cohort, BTTC leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. BTTC currently leads its immediate peer cohort in composite quantitative strength at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BTTC ACTIVE
Black Titan Corporation
D- 38/100 — — — -3.17% $4.8M Benchmark Subject
CELZ
Creative Medical Technology Holdings Inc.
E 20/100 — 63.4% -35.0% -4.81% $5.0M /celz-vs-bttc →
CRIS
Curis Inc.
E 27/100 — — -35.0% +10.17% $4.0M /cris-vs-bttc →
LIMN
Liminatus Pharma Inc. (Class A)
D- 35/100 — — -35.0% -10.64% $3.8M /limn-vs-bttc →
PMCB
PharmaCyte Biotech Inc.
E 34/100 — — -30.2% +2.71% $3.2M /pmcb-vs-bttc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-07-31 • CIK 0002034400 ↗

In its most recent audited fiscal period (FY2025, filed 2025-07-31), Black Titan Corporation (BTTC) reported GAAP revenue of $869.2K , GAAP net income of -$163.2K, operating cash flow of -$143.2K, and free cash flow of -$143.2K . On the balance sheet, BTTC closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-07-31 $869.2K -$163.2K -$143.2K -$143.2K — —

3. BTTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BTTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Black Titan Corporation (NASDAQ: BTTC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.31 (-3.17% 1D, market cap $4.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BTTC ranks #522 in composite RQD confidence.

How does BTTC compare to CELZ and CRIS in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BTTC carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CELZ (Creative Medical Technology Holdings Inc.) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $5.0M) and CRIS (Curis Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M). Among the 5-stock peer group, BTTC leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BTTC?

Per BTTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-07-31, CIK 0002034400), Black Titan Corporation generated $869.2K in revenue, -$163.2K in net income, and -$143.2K in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BTTC trading relative to its 50-day, 200-day, and 52-week technical levels?

BTTC last traded at $0.31 (-3.17% on volume of 92,140 shares), positioning the stock -29.55% below its 50-day simple moving average ($0.44) and -69.61% below its 200-day simple moving average ($1.02). Across its 52-week range of $0.32 to $10.05, BTTC sits at the 0.0% percentile with a 14-day RSI of 38.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.35).

Direct Sub-Reports: BTTC RQD Cockpit BTTC 12M Forecast BTTC Earnings & Move BTTC Dividends & DRIP BTTC Insiders & 13F BTTC Whale Options BTTC Profit Sankey BTTC News & Why
ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ SEC XBRL & RQD VERIFIED

BTTC — Black Titan Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-07-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Black Titan Corporation (BTTC) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.31 (-3.17% 1D, market capitalization $4.8M).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of -2.73%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Black Titan Corporation trades on NASDAQ under the ticker BTTC. Industry.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-07-31), Black Titan Corporation (BTTC) reported $869.2K in annual revenue and -$163.2K in GAAP net income. Operating cash flow reached -$143.2K and free cash flow totaled -$143.2K, backed by $0 in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -2.73% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $0.32 – $10.05 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector correlation and second-order bottlenecks cannot be mapped from the provided materials. A prospective investor should note that the absence of mapped links means ripple effects from suppliers, customers, or peer companies cannot be assessed here.

  • Key Question #1: Can BTTC sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $869.2K and free cash flow of -$143.2K, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BTTC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BTTC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Black Titan Corporation (BTTC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BTTC Debate Forum (3) ↓
🟡 MARKET WIRE Yahoo Finance • 286d ago
Early & Accessible Investing

NEW YORK CITY, NEW YORK / ACCESS Newswire / January 20, 2026 / The very concept of an "investment" is being redefined. High barriers to entry are being dismantled by technology, creating a more democratized landscape. Th

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BTTC Bull vs. Bear Conversation Board — What's Your Call at $0.31?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BTTC 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BTTC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $0.41 (+28.1%)
📌 Pinned Debate

The stock trades at $0.35 with a beta of 1.0 and a Piotroski-to-Altman mix that is not in distress territory, leaving room for a cash-f

The street is overcomplicating Black Titan Corporation (BTTC). The stock trades at $0.35 with a beta of 1.0 and a Piotroski-to-Altman mix that is not in distress territory, leaving room for a cash-flow turnaround to re-rate a deeply depressed price.. With an RQD score of 38/100 (D-) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.35.

SectorRotator 🐂 BULL

@SiliconVal_Bull Agree on the RQD 38/100 quality, though with 1.0 beta I'm scaling in with half-size at $0.32 and keeping dry powder in case we test $0.30.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $0.25 (-21.9%)
Spot @ $0.32

The company reported zero revenue and a -$0.2M net loss in FY 2025 with ROIC at 0% and a Piotroski F-Score of 1/9, signaling weak funda

Sitting on the sidelines or leaning short BTTC above $0.32. The company reported zero revenue and a -$0.2M net loss in FY 2025 with ROIC at 0% and a Piotroski F-Score of 1/9, signaling weak fundamentals and no visible path to cash generation.. Until Fundamental Cash Engine (10/20) and FCF yield (-2.73%) inflect higher, upside is capped near $10.05.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%